Compare KSCP & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSCP | LPCN |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 61.8M |
| IPO Year | 2022 | 2011 |
| Metric | KSCP | LPCN |
|---|---|---|
| Price | $3.58 | $7.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $16.67 | $15.00 |
| AVG Volume (30 Days) | ★ 576.8K | 96.6K |
| Earning Date | 05-13-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.54 | 46.18 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,335,000.00 | $1,976,677.00 |
| Revenue This Year | $9.63 | N/A |
| Revenue Next Year | $31.03 | $74.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.91 | N/A |
| 52 Week Low | $2.46 | $2.52 |
| 52 Week High | $10.13 | $12.37 |
| Indicator | KSCP | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 46.08 |
| Support Level | $2.92 | $2.87 |
| Resistance Level | $4.50 | $8.35 |
| Average True Range (ATR) | 0.48 | 0.68 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 6.09 | 29.30 |
Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.